PTGX insider sells 2,712 shares at $84.77 to cover taxes

Protagonist Therapeutics, Inc. (PTGX) reported an insider tax-related sale by its Chief Medical Officer.

Accepted by SEC EDGAR 11/19/2025 - 04:01 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Protagonist Therapeutics, Inc. (PTGX) reported an insider tax-related sale by its Chief Medical Officer. On 11/17/2025, Chief Medical Officer Arturo Molina reported selling 2,712 shares of common stock at a price of $84.77 per share. The sale was made to cover tax withholding obligations incurred when restricted stock units settled, rather than as an open-market discretionary sale.

Following this transaction, Arturo Molina beneficially owned 81,180 shares of Protagonist Therapeutics common stock in direct form. The filing was made by a single reporting person and does not list any derivative securities transactions.

Insider Trade Summary

Net Seller: 2,712 shares

Net Sell 1 txn

Insider MOLINA ARTURO MD

Role Chief Medical Officer

Sold 2,712 shs ($230K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,712	$84.77	$230K

Holdings After Transaction: Common Stock — 81,180 shares (Direct)

Footnotes (1)

1. F1. Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PTGX disclose in this Form 4?

The Form 4 reports that Chief Medical Officer Arturo Molina sold 2,712 shares of Protagonist Therapeutics common stock on 11/17/2025.

At what price were the PTGX shares sold in this insider transaction?

The reported sale price was $84.77 per share for the 2,712 shares of Protagonist Therapeutics common stock.

Why did the PTGX executive sell 2,712 shares?

The filing states the sale was to cover a tax withholding obligation incurred upon settlement of restricted stock units, not a discretionary sale of investment shares.

How many PTGX shares does the reporting person own after the transaction?

After the transaction, Chief Medical Officer Arturo Molina beneficially owned 81,180 shares of Protagonist Therapeutics common stock directly.

What is the role of the reporting person at Protagonist Therapeutics (PTGX)?

The reporting person, Arturo Molina, is identified as an Officer of Protagonist Therapeutics with the title Chief Medical Officer.

Does this PTGX Form 4 report any derivative securities transactions?

The table for derivative securities is present but has no reported transactions; the only detailed transaction involves common stock in Table I.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOLINA ARTURO MD

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CA 94560-1160

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		S		2,712(1)	D	$84.77	81,180	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units.

	/s/ Matthew Gosling, Attorney-in-Fact for Arturo Molina, MD	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.